Literature DB >> 33848452

Inflammasome Genetic Variants, Macrophage Function, and Clinical Outcomes in Cystic Fibrosis.

Andrew D Graustein1, William R Berrington1, Kati J Buckingham2, Felicia K Nguyen1, Lara L Joudeh1, Margaret Rosenfeld2,3, Michael J Bamshad2,4,5, Ronald L Gibson2,3, Thomas R Hawn1, Mary J Emond6.   

Abstract

Cystic fibrosis (CF) is characterized by chronic airway infection, inflammation, and tissue damage that lead to progressive respiratory failure. NLRP3 and NLRC4 are cytoplasmic pattern recognition receptors that activate the inflammasome, initiating a caspase-1-mediated response. We hypothesized that gain-of-function inflammasome responses are associated with worse outcomes in children with CF. We genotyped nonsynonymous variants in NLRP3 and the NLRC4 pathway from individuals in the EPIC (Early Pseudomonas Infection Control) Observational Study cohort and tested for association with CF outcomes. We generated knockouts of NLRP3 and NLRC4 in human macrophage-like cells and rescued knockouts with wild-type or variant forms of NLRP3 and NLRC4. We identified a SNP in NLRP3, p.(Q705K), that was associated with a higher rate of P. aeruginosa colonization (N = 609; P = 0.01; hazard ratio, 2.3 [Cox model]) and worsened lung function over time as measured by forced expiratory volume in 1 second (N = 445; P = 0.001 [generalized estimating equation]). We identified a SNP in NLRC4, p.(A929S), that was associated with a lower rate of P. aeruginosa colonization as part of a composite of rare variants (N = 405; P = 0.045; hazard ratio, 0.68 [Cox model]) and that was individually associated with protection from lung function decline (P < 0.001 [generalized estimating equation]). Rescue of the NLRP3 knockout with the p.(Q705K) variant produced significantly more IL-1β in response to NLRP3 stimulation than rescue with the wild type (P = 0.020 [Student's t test]). We identified a subset of children with CF at higher risk of early lung disease progression. Knowledge of these genetic modifiers could guide therapies targeting inflammasome pathways.

Entities:  

Keywords:  NLRC4; NLRP3; cystic fibrosis; inflammasome

Mesh:

Substances:

Year:  2021        PMID: 33848452      PMCID: PMC8399576          DOI: 10.1165/rcmb.2020-0257OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  50 in total

Review 1.  The inflammasomes.

Authors:  Kate Schroder; Jurg Tschopp
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  The secretion of IL-1β and options for release.

Authors:  Patrizia Piccioli; Anna Rubartelli
Journal:  Semin Immunol       Date:  2013-11-05       Impact factor: 11.130

3.  Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs.

Authors:  Peter Jorth; Benjamin J Staudinger; Xia Wu; Katherine B Hisert; Hillary Hayden; Jayanthi Garudathri; Christopher L Harding; Matthew C Radey; Amir Rezayat; Gilbert Bautista; William R Berrington; Amanda F Goddard; Chunxiang Zheng; Angus Angermeyer; Mitchell J Brittnacher; Jacob Kitzman; Jay Shendure; Corinne L Fligner; John Mittler; Moira L Aitken; Colin Manoil; James E Bruce; Timothy L Yahr; Pradeep K Singh
Journal:  Cell Host Microbe       Date:  2015-08-20       Impact factor: 21.023

4.  Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease.

Authors:  Jessica E Pittman; Elizabeth H Calloway; Michelle Kiser; John Yeatts; Stephanie D Davis; Mitchell L Drumm; Michael S Schechter; Margaret W Leigh; Mary Emond; Annelies Van Rie; Michael R Knowles
Journal:  Pediatr Pulmonol       Date:  2010-12-30

Review 5.  Innate and Adaptive Immunity in Cystic Fibrosis.

Authors:  Emanuela M Bruscia; Tracey L Bonfield
Journal:  Clin Chest Med       Date:  2015-12-28       Impact factor: 2.878

6.  Inflammatory cytokines in cystic fibrosis lungs.

Authors:  T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

7.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

8.  Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin.

Authors:  Karla L Lightfield; Jenny Persson; Sky W Brubaker; Chelsea E Witte; Jakob von Moltke; Eric A Dunipace; Thomas Henry; Yao-Hui Sun; Dragana Cado; William F Dietrich; Denise M Monack; Renée M Tsolis; Russell E Vance
Journal:  Nat Immunol       Date:  2008-08-24       Impact factor: 25.606

9.  Mitochondrial Ca2+-dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis.

Authors:  Alessandro Rimessi; Valentino Bezzerri; Simone Patergnani; Saverio Marchi; Giulio Cabrini; Paolo Pinton
Journal:  Nat Commun       Date:  2015-02-04       Impact factor: 14.919

10.  Polymorphisms in CARD8 and NLRP3 are associated with extrapulmonary TB and poor clinical outcome in active TB in Ethiopia.

Authors:  Ebba Abate; Robert Blomgran; Deepti Verma; Maria Lerm; Mats Fredrikson; Meseret Belayneh; Peter Söderkvist; Olle Stendahl; Thomas Schön
Journal:  Sci Rep       Date:  2019-02-28       Impact factor: 4.379

View more
  1 in total

1.  Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-γ release assay conversion.

Authors:  Jason D Simmons; Phu T Van; Catherine M Stein; Violet Chihota; Thobani Ntshiqa; Pholo Maenetje; Glenna J Peterson; Anthony Reynolds; Penelope Benchek; Kavindhran Velen; Katherine L Fielding; Alison D Grant; Andrew D Graustein; Felicia K Nguyen; Chetan Seshadri; Raphael Gottardo; Harriet Mayanja-Kizza; Robert S Wallis; Gavin Churchyard; W Henry Boom; Thomas R Hawn
Journal:  J Clin Invest       Date:  2021-07-15       Impact factor: 19.456

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.